Non-Hallucinogenic Psychedelic Treatment For Mental Health Disorders Shows Potential To Be Dosed Orally [Benzinga]
Thursday, July 25, 2024 1 min read
Key Takeaway: Enveric Biosciences has reported promising preclinical results for its oral drug candidate, EB-003, aimed at treating serious mental health disorders. Unlike traditional psychedelics, EB-003 is designed to be non-hallucinogenic, potentially increasing its safety profile. The drug demonstrated significant brain exposure in rodent models, suggesting its therapeutic potential.
Price reaction · baseline $86.22 (2024-07-24 close) · hit pre-market · 1 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
-1.7%
Market Sentiment Analysis
POSITIVE FACTORS
Positive preclinical results for EB-003
Designed to treat serious mental health disorders
Non-hallucinogenic effects enhance patient safety
Significant brain exposure at therapeutic doses
Full Press Release Details
Psychedelics biotech Enveric Biosciences announced positive preclinical results of its EB-003 drug candidate to be delivered via oral administration. EB-003 is a new, neuroplastogenic molecule designed to treat serious mental health disorders without the hallucinogenic effect typically associated with DMT (N,N-Dimethyltryptamine) and other psychedelic compounds. The results indicate that oral administration of EB-003 provides significant brain exposure in rodent models at potential therapeutic doses.
Full Article >>
Frequently Asked Questions
What is EB-003?
EB-003 is a neuroplastogenic molecule developed by Enveric Biosciences for treating mental health disorders.
How is EB-003 administered?
EB-003 is designed for oral administration, providing significant brain exposure.
What are the benefits of EB-003?
EB-003 offers a non-hallucinogenic treatment option, enhancing safety for patients.
What were the results of the preclinical study?
The preclinical results indicated significant brain exposure at potential therapeutic doses in rodent models.